Tag Archives: Theratechnologies

Theratechnologies (THTX) Receives a Buy from Mackie Research

In a report issued on September 10, Andre Uddin from Mackie Research reiterated a Buy rating on Theratechnologies (NASDAQ: THTX), with a price target of C$4.50. The company’s shares closed last Thursday at $2.22. The word on The Street in

Theratechnologies (THTX) Gets a Hold Rating from RBC Capital

In a report issued on July 15, Brian Abrahams from RBC Capital maintained a Hold rating on Theratechnologies (THTX – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $2.22. According to TipRanks.com, Abrahams

Canaccord Genuity Initiates a Buy Rating on Theratechnologies (THTX)

In a report released today, Michael Walkley from Canaccord Genuity initiated coverage with a Buy rating on Theratechnologies (THTX – Research Report) and a price target of $444.00. The company’s shares closed last Wednesday at $2.16. According to TipRanks.com, Walkley

Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX), Misonix (NASDAQ: MSON) and Zymeworks (NYSE: ZYME)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theratechnologies (THTX – Research Report), Misonix (MSON – Research Report) and Zymeworks (ZYME – Research Report) with bullish sentiments. Theratechnologies (THTX) Canaccord

Echelon Wealth Partners Maintains a Buy Rating on Theratechnologies (THTX)

Echelon Wealth Partners analyst Douglas Loe maintained a Buy rating on Theratechnologies (THTX – Research Report) on July 6 and set a price target of C$11.00. The company’s shares closed last Tuesday at $2.06. According to TipRanks.com, Loe is a

Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX) and Ascendis Pharma (NASDAQ: ASND)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Theratechnologies (THTX – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments. Theratechnologies (THTX) Canaccord Genuity analyst Edward Nash